Ruud Dobber, EVP BioPharmaceuticals Business Unit and Dave Fredrickson, EVP Oncology Business Unit, share highlights from AstraZeneca's Q3 2019 financial results. We announced continued strong top-line performance for the quarter underpinning confidence in sustainable growth.
View our Q3 2019 Results: [ Ссылка ]
----------------------------------------
Global site: [ Ссылка ]
Careers site: [ Ссылка ]
Follow us:
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]
Facebook: [ Ссылка ]
